Advanced search
Publication Cover
Expert Review of Hematology Volume 14, 2021 - Issue 1
Submit an article Journal homepage
412
Views
6
CrossRef citations to date
0
Altmetric
Drug Profile

A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma

Shambavi RichardDivision of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USACorrespondence[email protected]
View further author information
,
Sundar JagannathDivision of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Hearn Jay ChoDivision of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Samir ParekhDivision of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Deepu MadduriDivision of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Joshua RichterDivision of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
&
Ajai ChariDivision of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-0405-7480View further author information
ORCID Icon show all
Pages 31-45 | Received 01 Oct 2020, Accepted 30 Nov 2020, Published online: 17 Dec 2020

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Xavier Leleu, Ajai Chari, Shambavi Richard, Monica Khurana, Akeem Yusuf & Saad Z. Usmani. (2021) A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly. Expert Review of Hematology 14:12, pages 1049-1058.
Read now

Articles from other publishers (5)

Khalid Ahmed Al-Anazi. 2023. Recent Updates on Multiple Myeloma. Recent Updates on Multiple Myeloma.
Zdeněk Adam, Luděk Pour, Marta Krejčí, David Zeman, Zdeněk Řehák, Renata Koukalová, Viera Sandecká, Martin Štork & Zdeněk Král. (2022) Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients. Onkologie 16:Suppl. B, pages 61-82.
Crossref
Larry D Anderson Jr. (2022) Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncology 18:3, pages 277-289.
Crossref
Shansa Pranami E. Jayaweera, Sacheela Prasadi Wanigasinghe Kanakanamge, Dharshika Rajalingam & Gayathri N. Silva. (2021) Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma. Frontiers in Oncology 11.
Crossref
Massimo Martino, Filippo Antonio Canale, Caterina Alati, Iolanda Donatella Vincelli, Tiziana Moscato, Gaetana Porto, Barbara Loteta, Virginia Naso, Massimiliano Mazza, Fabio Nicolini, Andrea Ghelli Luserna di Rorà, Giorgia Simonetti, Sonia Ronconi, Michela Ceccolini, Gerardo Musuraca, Giovanni Martinelli & Claudio Cerchione. (2021) CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. Cancers 13:11, pages 2639.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.